Gene Ther Mol Biol Vol 10, 255-262,
2006
Isolation of genes
controlling apoptosis through their effects on cell survival
Gwyn T. Williams1,*, Jane P. Hughes1,3,
Victoria Stoneman1,4, Claire L. Anderson1, Nicola J.
McCarthy1 Mirna Mourtada-Maarabouni1, Mark Pickard1,
Vanessa L. Hedge1, Ian Trayner2, Farzin Farzaneh2
1Institute for Science and Technology in Medicine,
Huxley Building, Keele University, Keele, ST5 5BG, UK
2King's College London, Department of Haematological
and Molecular Medicine, The Rayne Institute, 123 Coldharbour Lane, London SE5
9NU, UK
3Present address; Neurology and GI Centre of
Excellence for Drug Discovery, GlaxoSmithKline Research and Development
Limited, New Frontiers Science Park, Third Avenue, Harlow CM19 5AW, Essex, UK
4Present address; Department of Medicine, University
of Cambridge, ACCI Level 6 Box 110, Addenbrookes Hospital, Hills Road,
Cambridge, UK
__________________________________________________________________________________
*Correspondence: Prof. Gwyn T. Williams, Institute for
Science and Technology in Medicine, Huxley Building, Keele University, Keele,
ST5 5BG, UK; Phone 44-1782-583032; Fax 44-1782-583516; E-mail g.t.williams@keele.ac.uk
Key words: apoptosis, forward genetics, functional cloning,
retroviral insertional mutagenesis, oncogenes, tumour suppressor genes
Abbreviations: Complementary DNA, (cDNA); Factor-dependent continuous cell line from the Paterson Institute, (FDCP-1); Interleukin-3, (IL-3); Phytohaemagglutinin, (PHA); Polymerase chain reaction, (PCR); Receptor for activated protein kinase C 1, (RACK1); Retroviral insertional mutagenesis, (RIM); Vacuolar ATPase, (vATPase); Walter and Elisa Hall Institute-105.726, (WEHI-105.726)
Summary
The
identification of the most suitable molecular targets for gene and drug therapy
is the crucial first step in the development of new disease treatments. The
rational identification of such targets depends on a detailed understanding of
the pathological changes occuring at the molecular level. We have applied
forward genetics approaches to the identification of the critical genes involved
in the control of apoptosis in mammalian cells, since defective control of
apoptosis underlies many diseases, including cancer and neurodegenerative
diseases. We have identified two groups of genes by their effects on cell
survival using retroviral cDNA functional expression cloning and retroviral
insertional mutagenesis. The identification of these novel genes opens up new
areas for apoptosis research and subsequently for the development of new gene
and drug therapies.
Apoptosis is now recognised as central to mammalian
cell biology in general- no picture of any human or other mammalian system can
be accepted as complete without some consideration of the potential role played
by apoptosis. Apoptosis is consequently of profound significance in physiology,
pathology and therapeutic medicine.
The analysis of the molecular mechanisms involved in
apoptosis is therefore of great importance in developing gene and drug
therapies for the many diseases where the control of apoptosis is perturbed. Apoptosis
dysfunction occurs, for instance, in neurodegenerative diseases (too much
apoptosis) and in autoimmune and neoplastic diseases (too little apoptosis)
(Williams and Smith, 1993; Thompson, 1995; Hale et al, 1996;). Much cancer
therapy, to quote an important example, relies on inducing apoptosis in tumour
cells (Kerr et al, 1994). Since our knowledge of the molecular control of
apoptosis is still incomplete, the identification of the genes involved in cell
death and survival is of major importance in defining targets for rational
design of gene and drug therapies.
The control of apoptosis is complex (e.g. Hengartner,
2000) and involves many genes. Some of these genes are now relatively well
characterised, e.g. the bcl-2 family (Cory and Adams, 2002) and the caspase
family (Thornberry and Lazebnik, 1998), but it is likely that many others have
yet to be identified. Many strategies, such as isolation of proteins through
their affinity for known components of the apoptosis machinery, are currently
being used to identify the missing molecules. We have chosen to identify genes
controlling apoptosis and cell survival through the biological effects of the
genes themselves on mammalian cells. This approach, sometimes known as forward
genetics (Stark and Gudkov, 1999), is independent of previous knowledge and
both can and does result in the identification of entirely novel and
unpredicted components. This strategy also focuses automatically on those
components which can actually affect the cell death/survival decision within
the cell, as distinct from those associated with cell death but not having any
controlling role. It is this first group which are likely to be of the greatest
biological and clinical importance and which provide the best targets for gene
and drug therapies.
Earlier work from Kimchi and co-workers using this sort of strategy resulted in the isolation of several important genes (Deiss et al, 1995; Cohen et al, 1997) including DAP-kinase, which can play an important role in metastasis (Inbal et al, 1997). Other groups have also used this approach, resulting in the isolation of several interesting and important genes (e.g. Hitoshi et al, 1998). We have used two related approaches within this general strategy; firstly, we have transfected cDNA libraries in expression vectors into clonal mammalian cells which are uniformly susceptible to apoptosis stimuli (Figure 1). The isolation and analysis of the cDNA clones expressed by cells which survive the stimulation of apoptosis identifies candidate apoptosis-controlling genes. The activity of these genes can later be confirmed by isolation of the sequence, re-cloning into an expression vector and expressing in fresh host cells which are then challenged with apoptosis stimuli. Secondly, we have infected clonal apoptosis-sensitive cell lines with retroviruses and again induced apoptosis under conditions where fewer than 1 in 104 host cells normally survive (Figure 2). In this case, the amplification of the host DNA flanking the inserted retrovirus using inverse PCR allows the identification of the gene affected by the insertion to produce the apoptosis-resistant phenotype. Our use of these two strategies resulted in the identification of several known apoptosis-controlling genes. The additional isolation of a larger number of genes not previously known to be involved in this process indicates that many more components of the cellular apoptosis-controlling machinery still remain to be identified.
A. Cell culture
The W7.2 mouse thymoma cell
line, originally derived from line WEHI-105.726 (Danielsen et al, 1983), and
the FDCP1 haemopoietic cell line (Dexter et al, 1980), used as hosts were grown
in RPMI 1640 with 10% fetal calf serum (Hyclone, UT, USA) at 370C in
a 5% CO2 humidified incubator. FDCP-1 medium was supplemented with
mouse IL-3 (Dexter et al, 1980; McCarthy, 1993). Both cell lines were cloned in
soft agar (McCarthy, 1993; Mourtada-Maarabouni et al, 2003) and
apoptosis-sensitive clones containing less than 1 in 104 apoptosis-resistant
cells were identified and grown to produce large stocks which were stored in
liquid nitrogen. These target cells were used after thawing and a minimal
number of subcultures in order to minimise the appearance of spontaneously
apoptosis-resistant cells. The clones used in the present study were FDCP-1B, which had an even lower frequency of spontaneous IL-3
independence of 2(±1.9) x10-6) (McCarthy, 1993), and W7.2c
(Mourtada-Maarabouni et al, 2003).

Figure
1. Production of apoptosis-deficient cell clones by retroviral cDNA
library functional expression cloning.

B. cDNA functional
expression cloning
Target cells were treated
with 90 ng/ml tunicamycin at 3 x 105 cells/ml for 18 hours and
washed before infection with retrovirus. Two different cDNA expression
libraries were used, both in the pRUFneo retroviral expression vector (Rayner
and Gonda 1994). cDNA for the first library was derived from human bone marrow
stromal cells (Zannetino et al, 1996), and for the second library from FDCP1
cells (Rayner and Gonda, 1994)). y2 ecotropic murine packaging
cells producing the libraries seeded at 5 x 106 cells per 225cm2
flask were grown overnight to about 60% confluence and g-irradiated using a 60Co
source (2500cGy). The supernatant was removed and 25ml of W7.2c cell suspension
was added with 8mg/ml polybrene for 3 days co-culture. The
cells in suspension were centrifuged and washed before being stored in aliquots
in liquid nitrogen.
C. Selection of
apoptosis-resistant clones
Several selection protocols
were employed at different times to allow the identification of a range of
different apoptosis-resistant mutant cells. Selection with g-radiation was carried out
using a 60Co radiation source delivering a dose of 500-1000 cGy.
Selection with dexamethasone (20- 50nM) was carried out for 6 days, after which
time the cells were washed to remove the dexamethasone prior to cloning in soft
agar (Mourtada-Maarabouni et al, 2003). Continuous treatment with dexamethasone
during cloning was avoided since this would not allow the isolation of cells
resistant to the apoptosis-inducing effects alone- any colonies growing in the
continuous presence of dexamethasone would have to be resistant to its
cytostatic effects as well.
Selection of W7.2c cells with
Phytohaemagglutinin (PHA; HA16, Murex Biotech UK), either as the sole stimulus
or after irradiation or dexamethasone treatment, was carried out by including
the PHA in the soft agar cloning dishes at final concentrations of 5-10mg/ml.
cDNA inserts from
apoptosis-resistant clones were amplified by PCR, using primers complementary
to the adjoining vector, and sequenced (Mourtada-Maarabouni et al, 2003).
D. Retroviral Insertional
Mutagenesis (RIM)
Target W7.2c and FDCP-1B
cells were infected with the retroviral vector pBABEpuro (Morgenstern and Land,
1990) produced in the ecotropic packaging cell line GP+E86 (Miller and Miller,
1992). Target cells were pre-incubated with tunicamycin and washed before
co-culture with gamma-irradiated packaging cells for 2 days in the presence of
polybrene. After several infection cycles, infected W7.2c cells were washed and
selected as above. Infected FDCP-1B cells were washed
3 x to remove IL-3 and incubated for 24 hours prior to cloning in soft agar;
cells were incubated for a total of 7 days without IL-3, and IL-3 was then
added to the soft agar. The site of retroviral insertion in surviving
clones was determined by inverse PCR.
A. cDNA
functional expression cloning
The use of techniques which depend on an unbiased
screen based solely on the function of the gene has the potential to identify
many genes which act by highly diverse mechanisms. This diversity is
demonstrated in Table 1 which lists
18 genes isolated from W7.2c cells which survived apoptotic stimuli. They are
therefore candidate apoptosis-regulating genes. However it is likely that
several will be false positives- e.g. isolated from cells fortuitously carrying
genomic mutations giving resistance to apoptosis. For several of the clones
however, apoptosis-suppressing activity has been confirmed by re-expressing the
inserts in fresh host cells and challenging with apoptosis-inducing stimuli
(e.g. Protein phosphatase 4, RACK1 and rFau (antisense to Fau).
The sequences isolated by cDNA functional expression
cloning include full protein-coding sequences, such as Onzin/PLAC8, as well as
partial coding sequences, such as Protein Phosphatase 4, and antisense
sequences, such as rFau. These sequences can be assumed to modulate apoptosis
in very different ways. PLAC8/ Onzin, for example, is likely to act as an
inhibitor of apoptosis (Rogulski et al, 2005), whereas the partial mRNA
sequence of Protein Phosphatase 4 identified appears to act by inhibiting the
activity of endogenous pro-apoptotic Protein Phosphatase 4 (Mourtada-Maarabouni
et al, 2003). The partial antisense sequence of Fau identified is likely to
suppress apoptosis by hybridising to the mRNA of endogenous pro-apoptotic Fau
(Mourtada-Maarabouni et al, 2004).
Table
1. Candidate
apoptosis-regulating genes identified by cDNA functional expression cloning
|
Gene name(s) |
cDNA library selected |
Challenge for isolation |
Host cell for isolation |
cDNA originally isolated |
Confirmation of effects on cell survival |
|
PPP4C; Protein
Phosphatase 4, catalytic subunit |
Mouse FDCP1 cDNA in
retroviral vector pRUFneo (Rayner and Gonda, 1994) |
Dexamethasone followed
by g-radiation |
W7.2c (Mourtada-Maarabouni
et al, 2003) |
Partial, sense |
Yes
(Mourtada-Maarabouni et al, 2003) |
|
Fau; MNSFbeta |
Mouse FDCP1 cDNA in
retroviral vector pRUFneo (Rayner and Gonda, 1994) |
Dexamethasone followed
by g-radiation |
W7.2c
(Mourtada-Maarabouni et al, 2003) |
Partial, antisense |
Yes (Mourtada-Maarabouni et
al, 2004) |
|
Gnb2l1/RACK1; Receptor
for Active C Kinase 1 |
Mouse FDCP1 cDNA in
retroviral vector pRUFneo (Rayner and Gonda, 1994) |
g-radiation followed by
PHA |
W7.2c
(Mourtada-Maarabouni et al, 2003) |
Partial, sense |
Yes (Mourtada-Maarabouni
et al, 2005) |
|
Atp6v1e1; Vacuolar/
lysosomal ATPase, subunit E |
Mouse FDCP1 cDNA in
retroviral vector pRUFneo (Rayner and Gonda, 1994) |
g-radiation followed by
PHA |
W7.2c
(Mourtada-Maarabouni et al, 2003) |
Partial, sense |
Yes (Anderson and Williams,
2003) |
|
Gas5; Growth Arrest
Specific transcript 5 |
Mouse FDCP1 cDNA in
retroviral vector pRUFneo (Rayner and Gonda, 1994) |
g-radiation |
W7.2c
(Mourtada-Maarabouni et al, 2003) |
Not applicable |
- |
|
Plac8; Onzin; C15 |
Mouse FDCP1 cDNA in
retroviral vector pRUFneo (Rayner and Gonda, 1994) |
g-radiation followed by
PHA |
W7.2c
(Mourtada-Maarabouni et al, 2003) |
Full coding sequence,
sense |
Yes (Rogulski et al,
2005) |
|
Limk2;
LIM-motif-containing protein kinase 2 |
Mouse FDCP1 cDNA in
retroviral vector pRUFneo (Rayner and Gonda, 1994) |
Cloning in PHA |
W7.2c
(Mourtada-Maarabouni et al, 2003) |
Partial, sense |
- |
|
Fus; Tls; Pigpen |
Mouse FDCP1 cDNA in
retroviral vector pRUFneo (Rayner and Gonda, 1994) |
g-radiation followed by
PHA |
W7.2c
(Mourtada-Maarabouni et al, 2003) |
Partial, sense |
- |
|
Ucp2; Uncoupling
protein 2 |
Mouse FDCP1 cDNA in
retroviral vector pRUFneo (Rayner and Gonda, 1994) |
Dexamethasone followed
by PHA |
W7.2c
(Mourtada-Maarabouni et al, 2003) |
Partial, sense |
- |
|
Prtn3; mPR3; Proteinase
3 |
Mouse FDCP1 cDNA in
retroviral vector pRUFneo (Rayner and Gonda, 1994) |
Etoposide |
W7.2c
(Mourtada-Maarabouni et al, 2003) |
Partial, sense |
- |
|
HTRA1; PRSS11; HTRA
serine peptidase 1 |
Human bone marrow
stromal cells (Zannettino et al, 1996) |
PHA |
W7.2c
(Mourtada-Maarabouni et al, 2003) |
Partial, sense |
- |
|
Gene name(s) |
cDNA library selected |
Challenge for isolation |
Host cell for isolation |
cDNA originally isolated |
Confirmation of effects on cell survival |
|
RPLP1; Ribosomal
protein, large, P1 |
Human bone marrow
stromal cells (Zannettino et al, 1996) |
PHA |
Full coding sequence,
sense |
- |
|
|
TncRNA;
Trophoblast-derived noncoding RNA |
Human bone marrow
stromal cells (Zannettino et al, 1996) |
PHA |
W7.2c
(Mourtada-Maarabouni et al, 2003) |
Not applicable |
- |
|
S100A6; S100 calcium
binding protein A6 (calcyclin) |
Human bone marrow
stromal cells (Zannettino et al, 1996) |
PHA |
W7.2c
(Mourtada-Maarabouni et al, 2003) |
Partial, sense |
- |
|
SEC61A1; HSEC61;
protein transport protein SEC61 alpha subunit |
Human bone marrow
stromal cells (Zannettino et al, 1996) |
PHA |
W7.2c
(Mourtada-Maarabouni et al, 2003) |
Partial, sense |
- |
HNRPD; AUF1A; Heterogeneous nuclear ribonucleoprotein D; AU-rich
element RNA binding
protein 1 |
Human bone marrow
stromal cells (Zannettino et al, 1996) |
PHA |
W7.2c
(Mourtada-Maarabouni et al, 2003) |
Partial, sense |
- |
|
TNFAIP8; GG2-1, SCC-S2,
MDC-3.13; Tumor necrosis factor, alpha-induced protein 8 |
Human bone marrow
stromal cells (Zannettino et al, 1996) |
PHA |
W7.2c
(Mourtada-Maarabouni et al, 2003) |
Partial, sense |
- |
|
GMFB; Glia maturation
factor beta |
Human bone marrow
stromal cells (Zannettino et al, 1996) |
PHA |
W7.2c
(Mourtada-Maarabouni et al, 2003) |
Partial, sense |
- |
|
CTSD; CPSD; Cathepsin D |
Human bone marrow
stromal cells (Zannettino et al, 1996) |
PHA |
W7.2c
(Mourtada-Maarabouni et al, 2003) |
Partial, sense |
Yes, e.g.
Liaudet-Coopman et al, 2006 |
In other cases, mutated/truncated proteins may be produced which can have either
dominant negative inhibitory activity, or which may be constitutively
activated.
The anti-apoptotic effect of the partial sense protein
phosphatase 4 sequence was confirmed by isolation of the cDNA insert from the
genomic DNA of the corresponding W7.2c clone using PCR and subsequent
expression in fresh host cells (Mourtada-Maarabouni et al, 2003). Many of the
proteins important in the control of apoptosis are regulated by phosphorylation
and dephosphorylation, e.g. the Bcl-2 family of apoptosis regulators (e.g. Deng
et al, 1998; Chiang et al, 2001). The identification of Protein Phosphatase 4
as functionally important in apoptosis suggests that it may act on one or more
of these. The sequence antisense to Fau is also of particular significance
since a Fau antisense sequence is also found in the Finkel-Biskis-Reilly murine
sarcoma virus (Finkel et al, 1976). The anti-apoptotic effect of Fau antisense
sequences, and the pro-apoptotic effects of Fau, have been confirmed directly
(Mourtada-Maarabouni et al, 2004). Fau may therefore act as a tumour
suppressor, and down-regulation of Fau may be important in oncogenesis.
One of the cDNA sequences isolated by sequential
selection with g-radiation and PHA is a
partial cDNA for the receptor for activated protein kinase C (RACK1), which
includes the 3'-untranslated sequence of the mRNA. Although this sequence does
not contain the full coding sequence of RACK1, it up-regulates endogenous
RACK1, presumably by interacting with endogenous regulatory molecules. Studies
on the expression of full length RACK1 have confirmed its anti-apoptotic
activity, which may be related to its established interactions with Src kinases
(Chang et al, 2002), integrins (Liliental and Chang, 1998) or other molecules
(Mourtada-Maarabouni et al, 2005).
Vacuolar ATPase subunit E was identified in two
separate screens. Firstly, by temporary withdrawal of IL-3 from BAF-3 IL-3-dependent
cells (Anderson and Williams, 2003) and, independently, by selection of W7.2c
cells with g-radiation followed by PHA. In both cases the
suppression of apoptosis appeared to be due to indirect effects on the
endogenous vATPase through regulatory molecules which modulate the activity of
the vATPase. This proton pump can affect both cytoplasmic and
vacuolar/lysosomal pH, as well as other aspects of cell metabolism (reviewed by
Nishi and Forgac, 2002).
B. Retroviral
Insertional Mutagenesis (RIM)
The information which has flowed from the human and
mouse genome projects over the past few years has been very valuable in
allowing the rapid identification of the sites of retroviral insertion in cells
showing resistance to apoptosis (Table 2).
This has made it possible to identify the flanking sequences obtained by
inverse PCR (e.g. Nowrouzi et al, 2006; Shin et al, 2004) and so to suggest the
identity of novel candidate apoptosis-regulating genes. Two of the genes
identified by RIM have been shown to be involved in the control of apoptosis.
Firstly, Notch1 has been shown to play a crucial role in the control of cell
fate, including the control of apoptosis (e.g. Jundt et al, 2002). Secondly,
the insulin-like growth factor receptor (Igf1r) has been shown to regulate
apoptosis and to play an important role in oncogenesis in many tissues (e.g.
Roschier et al, 2001). Spink2, on the other hand, could not be demonstrated to
play any significant role in apoptosis in the Jurkat human T-cell line, or in
the TF-1 human growth factor dependent cell line (Hedge and Williams,
unpublished work). This serves as a reminder that the candidate
apoptosis-regulating genes listed in both Table
1 and Table 2 are bound to
include some false positives. Further studies are required in each case to
confirm or refute the potential roles in apoptosis control.
In the present paper we have confirmed that forward
genetics, either using cDNA functional expression cloning or using RIM, is a
very valuable strategy for the analysis of the molecular controls on apoptosis.
In several cases, entirely unpredicted genes have been identified, each of
which opens up a new avenue for apoptosis research. Since regulation of
apoptosis is crucial to many diseases, this molecular dissection of apoptosis identifies
novel targets for the gene and drug therapy of these diseases.
We thank the Wellcome Trust and BBSRC UK for financial
support and Dr. Janet Meredith for subcloning candidate genes.
Table
2. Candidate
apoptosis-regulating genes identified by retroviral insertional mutagenesis
|
Mouse chromosome insertion |
Gene closest to insertion |
Gene sequence associated with
insertion |
Confirmation of effects on cell
survival |
|
10 |
Cdh23;
Cadherin-23; Otocadherin (insertion into intron) |
GI:24475914 |
- |
|
3 |
Gstm1;
Glutathione-S-Transferase Mu-1 (insertion into intron) |
GI: 68051724
|
- |
|
2 |
Notch1 |
GI
:31543331 |
Yes, e.g. Jundt et al, 2002 |
|
14 |
Pheromone
receptor V3R6 |
GI:26083204 |
- |
|
5 |
Spink2;
Serine peptidase inhibitor, Kazal type 2 |
GI:34304086
|
- |
|
7 |
Igf1r;
insulin-like growth factor I receptor |
GI:3025893 |
Yes, e.g. Roschier et al, 2001 |
Anderson C L and Williams G T (2003)
Apoptosis gene hunting using retroviral expression cloning. SciWorld J
3, 51-58.
Chang B Y, Harte R A, Cartwright C A (2002) RACK1:
a novel substrate for the Src protein-tyrosine kinase. Oncogene 21,
7619-7629.
Chiang C W, Harris G, Ellig C, Masters S C,
Subramanian R, Shenolikar S, Wadzinski B E, Yang E (2001) Protein
phosphatase 2A activates the proapoptotic function of BAD in interleukin-3-dependent
lymphoid cells by a mechanism requiring 14-3-3 dissociation. Blood 97,
1289-1297.
Cohen O, Feinstein E, Kimchi A (1997) DAP-kinase
is a Ca2+ calmodulin-dependent cytoskeletal-associated protein kinase with cell
death-inducing functions that depend on its catalytic activity. EMBO J
16, 998-1008.
Cory S, Adams J M (2002) The BCL2 family:
Regulators of the cellular life-or-death switch. Nat Rev Cancer 2,
647-656.
Danielsen M, Peterson D O, Stallcup M R (1983)
Immunological selection of variant mouse lymphoid cells with altered
glucocorticoid responsiveness. Mol Cell Biol 3, 1310-1316.
Deiss L P, Feinstein E, Berissi H, Cohen O, Kimchi A
(1995) Identification of a novel serine threonine kinase and a novel
15-kd protein as potential mediators of the gamma-interferon-induced
cell-death. Genes Dev 9, 15-30.
Deng X, Ito T, Carr B, Mumby M, Stratford May Jr M (1998)
Reversible phosphorylation of Bcl2 following interleukin-3 or bryostatin 1 is
mediated by direct interaction with PP2A. J Biol Chem 273, 34157-34163.
Dexter T M, Garland J, Scott D, Scolnick E, Metcalf
D (1980) Growth of factor-dependent hematopoietic precursor cell-lines. J
Exp Med 152. 1036-1047.
Finkel M P, Reilly Jr C A, Biskis B O (1976) Recent
Results Cancer Res 54, 92-103.
Hale A J, Smith C A, Sutherland L C, Stoneman V E A,
Longthorne V L, Culhane A C, Williams G T (1996) Apoptosis: Molecular
regulation of cell death. Eur J Biochem 236, 1-26.
Hengartner M O (2000) The biochemistry of
apoptosis. Nature 407, 770-776.
Hitoshi Y, Lorens J, Kitada S I, Fisher J, LaBarge
M, Ring H Z, Francke U, Reed J C, Kinoshita S, Nolan G P (1998) Toso, a cell
surface specific regulator of Fas-induced apoptosis in T cells. Immunity
8, 461-471.
Inbal B, Cohen O, PolakCharcon S, Kopolovic J, Vadai
E, Eisenbach L, Kimchi A (1997) DAP kinase links the control of
apoptosis to metastasis. Nature 390, 180-184.
Jundt F, Anagnostopoulos I, Forster R, Mathas S,
Stein H, Dorken B (2002) Activated Notch1 signaling promotes tumor cell
proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood
99, 3398-3403.
Kerr J F R, Winterford C M, Harmon B V (1994) Apoptosis
- its significance in cancer and cancer-therapy. Cancer 73, 2013-2026.
Liaudet-Coopman E, Beaujouin M, Derocq D, Garcia M,
Glondu-Lassis M, Laurent-Matha V, Prebois C, Rochefort H, Vignon F (2006)
Cathepsin D: newly discovered functions of a long-standing aspartic protease in
cancer and apoptosis. Cancer Letts 237, 167-179.
Liliental J, Chang DD (1998) Rack1 a receptor
for activated protein kinase C interacts with integrin beta subunit. J Biol
Chem 273, 2379-2383.
McCarthy N J, (1993) Apoptosis induced by
cancer chemotherapeutic drugs and its genetic suppression. D. Phil (University
of Birmingham).
Miller D G and Miller A D (1992) Tunicamycin
treatment of CHO cells abrogates multiple blocks to retrovirus infection one of
which is due to a secreted inhibitor. J Virol 66, 78-84.
Morgenstern J P, Land H (1990) Advanced
mammalian gene-transfer - high titer retroviral vectors with multiple-drug
selection markers and a complementary helper-free packaging cell-line Nucl
Acid Res 18, 3587-3596.
Mourtada-Maarabouni M, Kirkham L, Farzaneh F,
Williams G T (2004) Regulation of apoptosis by fau revealed by
functional expression cloning and antisense expression. Oncogene 23,
9419-9426.
Mourtada-Maarabouni M, Kirkham L, Farzaneh F,
Williams G T, (2005) Functional expression cloning reveals a central
role for the receptor for activated protein kinase C 1 (RACK1) in T cell
apoptosis. J Leuk Biol 78, 503-514.
Mourtada-Maarabouni M, Kirkham L, Jenkins B, Rayner
J, Gonda T J, Starr R, Trayner I, Farzaneh F, Williams G T (2003)
Functional expression cloning reveals proapoptotic role for protein phosphatase
4. Cell Death Diff 10, 1016-1024.
Nishi T, Forgac M (2002) The vacuolar
(H+)-ATPases - Nature's most versatile proton pumps. Nat Rev Mol Cell Biol
3, 94-103.
Nowrouzi A, Dittrich M, Klanke C, Heinkelein M,
Rammling M, Dandekar T, von Kalle C, Rethwilm A (2006) Genome-wide
mapping of foamy virus vector integrations into a human cell line. J Gen
Virol 87, 1339-1347.
Rayner J R, Gonda T J (1994) A simple and
efficient procedure for generating stable expression libraries by cDNA cloning
in a retroviral vector. Mol Cell Biol 14, 880-887.
Rogulski K, Li Y J, Rothermund K, Pu L X, Watkins S,
Yi F H, Prochownik E V (2005) Onzin a c-Myc-repressed target promotes
survival and transformation by modulating the Akt-Mdm2-p53 pathway. Oncogene
24, 7524-7541
Roschier M, Kuusisto E, Suuronen T, Korhonen P,
Kyrylenko S, Salminen A (2001) Insulin-like growth factor binding
protein 5 and type-1 insulin-like growth factor receptor are differentially
regulated during apoptosis in cerebellar granule cells. J Neurochem 76,
11-20.
Shin M S, Fredrickson T N, Hartley J W, Suzuki T,
Agaki K, and Morse H C (2004) High-throughput retroviral tagging for
identification of genes involved in initiation and progression of mouse splenic
marginal zone lymphomas. Cancer Res 64, 4419-4427.
Stark G R, Gudkov A V (1999) Forward genetics in
mammalian cells: functional approaches to gene discovery. Hum Mol Genet
8, 1925-1938.
Thompson C B (1995) Apoptosis in the
pathogenesis and treatment of disease. Science 267, 1456-1462.
Thornberry N A, Lazebnik Y (1998) Caspases:
Enemies within. Science 281, 1312-1316.
Williams G T, Smith C A (1993) Molecular
regulation of apoptosis - genetic controls on cell-death. Cell 74,
777-779.
Zannettino
A C W, Rayner J R, Ashman L K, Gonda T J, Simmons P J (1996) A powerful
new technique for isolating genes encoding cell surface antigens using
retroviral expression cloning. J Immunol 156, 611-620.